Skip to search formSkip to main contentSkip to account menu

ibandronic acid

A third-generation amino-bisphosphonate with anti-resorptive and anti-hypercalcemic activities. Ibandronic acid binds to and adsorbs onto the surface… 
National Institutes of Health

Related topics

Related topics

11 relations
3 ML ibandronic acid 1 MG/ML Prefilled Syringe [Boniva]Ibandronate sodiumibandronic acid 150 MG Oral Tabletibandronic acid 150 MG Oral Tablet [Boniva]

Narrower (4)

BM 21.0955BondronatBonivaBonviva

Broader (3)

Bone Density Conservation AgentsDiphosphonatesIbandronate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2014
Review
2014
Which bisphosphonate to treat bone metastases?
2013
2013
Identification and management of osteoporosis in older adults
2012
2012
Zoledronic Acid
SummaryAbstractZoledronic acid (Zometa®), a third-generation amino-bisphosphonate, has been approved in the US, the EU and many… 
Review
2010
Review
2010
Renal function changes and NHS resource use in breast cancer patients with metastatic bone disease treated with IV zoledronic acid or oral ibandronic acid: a four-centre non-interventional study
Abstract Aims: To describe renal function monitoring practice in patients with metastatic bone disease (MBD) treated with IV… 
Review
2009
Review
2009
Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.
2008
2008
Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone disease
PurposeThis trial is the first to compare directly the clinical response to and safety of oral and intravenous (IV) ibandronic… 
Review
2008
Review
2008
Managing neoplastic bone disease with ibandronic acid: a preclinical and clinical data update.
BACKGROUND Bisphosphonates are the standard of care for treating and preventing the complications of bone metastases. Ibandronic… 
Review
2008
Review
2008
Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.
Zoledronic acid (Zometa is a third-generation nitrogen-containing parenteral bisphosphonate indicated for the treatment of bone… 
Review
2006
Review
2006
Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.
2006
2006
Long-Term Safety of Intravenous Ibandronic Acid for Up to 4 Years in Metastatic Breast Cancer
AbstractBackground and objective: Despite their widespread use in metastatic bone disease, some bisphosphonate drugs are… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)